Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31270535 | 0.85 | PLA2G7 (0.37) | GPR119NAMPTMCL1BAK1CSF1R | |
| SCHEMBL31270200 | 0.82 | GPR119 (0.45) | GPR119NAMPTCHEK2 | |
| SCHEMBL31269794 | 0.79 | GPR119 (0.51) | GPR119CHEK2PPARGPPARDCSF1R | |
| SCHEMBL29269441 | 0.77 | GPR119 (0.47) | GPR119CHEK2 | |
| SCHEMBL31270213 | 0.77 | GPR119 (0.40) | GPR119CHEK2PPARGPPARD | |
| SCHEMBL31270048 | 0.77 | GPR119 (0.41) | GPR119CHEK2 | |
| SCHEMBL31270140 | 0.74 | GPR119 (0.37) | GPR119CHEK2PPARGPPARD | |
| SCHEMBL15520515 | 0.74 | NAMPT (0.43) | KDM1ANAMPT | |
| SCHEMBL31270243 | 0.74 | SLC5A1 (0.45) | GPR119NAMPTCHEK2 | |
| SCHEMBL8567306 | 0.74 | NAMPT (0.46) | GPR119KDM1ANAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240415819-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | QLi5 Therapeutics AG (DE) | 2024-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240415819-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | PSMB5, PSMA5, PSMB1 | GPR119 4139/4885KDM1A 2153/4885NAMPT 2259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.